The Wellcome Trust and Medical Research Council (MRC) in London, UK are investing £8m in a new stem cell institute.
The Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute is expected to focus on key research areas including pluripotency, haematopoiesis, epithelial tissues, neural and cardiovascular stem cells.
The Wellcome Trust-MRC Cambridge Stem Cell Institute director Professor Austin Smith said the Institute will provide an environment for fundamental and translational researchers to work together.
"Our aim is to close the knowledge gap and drive stem cell research forward towards clinical applications," Professor Smith said.
"The world-class facilities will attract the best international talent from the fields of stem cell biology and regenerative medicine to pursue this goal."
The Institute, which is likely to be housed in an 8,000m2 facility on the Cambridge Biomedical Research Campus, will unite 30 research teams focusing on embryonic, adult and induced pluripotent cells.
The MRC chief executive Professor Sir John Savill said; "By joining forces with the Wellcome Trust to invest strategically in all areas of stem cell science, embracing both adult and embryonic stem cells, we will create a competitive and attractive environment for future commercial investment in regenerative medicine."
The scientists at the institute will work in collaboration with doctors and technology specialists in developing new therapeutics with a strong base of fundamental stem cell biology.
The Wellcome Trust director Sir Mark Walport said; "The new institute will play a vital role in accelerating our understanding health and disease, and in the development of new treatments, and will cement the UK’s position as a world-leader in stem cell research."
Image: The Wellcome Trust’s Gibbs Building on Euston Road. Photo: Courtesy of Edward.